Marc Fenster Profile
Marc Fenster

@Marcfenster1

Followers
239
Following
975
Media
3
Statuses
66

Gastroenterologist at Five Towns Gastroenterology, faculty @MontefioreNYC; former fellow @MontefioreNYC; Former Resident @MountSinaiNYC; @EinsteinMed alum

Joined August 2011
Don't wanna be here? Send us removal request.
@P_DeepakIBDMD
Parakkal Deepak MD, MS, FACG
2 years
Real-World Effectiveness of Ustekinumab in Ulcerative Colitis in a United States Multicenter Cohort Consortium led by @AndresYarur with the rest of us from the #REBOOTIBD consortium
Tweet card summary image
academic.oup.com
AbstractBackground. Pivotal trials have shown that ustekinumab is effective in ulcerative colitis (UC). However, the population included in these trials do
1
13
43
@yairlapid
יאיר לפיד - Yair Lapid
2 years
3 questions for the global far left: 1/14 Here’s the 1st question: How many Jews need to die before you stop blaming us for everything that happens? Because on that dark Saturday 2 weeks ago, 1,400 were murdered. How many more do you need? Ten thousand? 6 million?
598
3K
11K
@naftalibennett
Naftali Bennett נפתלי בנט
2 years
No, CNN, there aren’t “two sides” to the Gaza hospital story. Go do your goddamn job.
1K
3K
14K
@naftalibennett
Naftali Bennett נפתלי בנט
2 years
Make no mistake: Hamas is trying to show a “humane” face (“we’re taking good care of a hostage”), but this is what they actually did: - Burnt whole families - Shot a 6-month old baby in the head - Burnt a one year old baby - Cut the head off a baby - Shot a father that was
1K
5K
15K
@TreyYingst
Trey Yingst
2 years
Imagine the worst things possible that can be done to humans. Hamas did all of that and more to Israeli civilians. Babies beheaded. People burned alive in their homes. Women raped and dragged through the streets. Don’t look away.
4K
16K
47K
@P_DeepakIBDMD
Parakkal Deepak MD, MS, FACG
3 years
Presnting tmrw #Tu1806 REBOOT-IBD consortium N = 241 #UC pts started on 45 mg Upadacitinib in 11-center study @WUGastro @UChicagoIBD @mountsinaiIBD @BrookeArmyMed @bcm_gihep @MayoClinicGIHep @MedicalCollege @UMichGIHep @MonteGastro @IBDCedarsSinai @ClevelandClinic 👀Q&A #DDW2023
3
14
37
@AndrewMMoon
Andrew Moon
3 years
Gastroenterologists and hepatologists, what are your feelings on the stethoscope? Important diagnostic tool or merely an accessory to make you "look like a doctor" (see Clooney Fig 1). This @AmJGastro #RedSection piece may make you rethink your answer. https://t.co/A5nzirqCCn
19
30
135
@Bealoquebea
Beatriz Gros
3 years
Many of you know I love timelines & I have been updating the one on IBD trials/studies for some time🧵 The landscape is changing fast & there isnt enough space here to share all the content As such I have created a website to collect it all and to make it interactive
47
151
416
@DrReddyGI
Naveen Reddy
3 years
This entire review is good to save to brush up on uncommon, but easily missed/delayed diagnoses. Definitely things to consider if your basic algorithms aren't leading to an adequate response. #GITwitter #MedEd #MedTwitter
@AGA_CGH
CGH
3 years
February Editor's Essential Reading examines rare, overlooked, and underappreciated causes of recurrent abdominal pain. Learn more at https://t.co/EU58OJ4gTB
1
2
5
@AGA_CGH
CGH
3 years
February Editor's Essential Reading examines rare, overlooked, and underappreciated causes of recurrent abdominal pain. Learn more at https://t.co/EU58OJ4gTB
2
32
85
@P_DeepakIBDMD
Parakkal Deepak MD, MS, FACG
3 years
🌟 🌟 work from our team #CCCongress23 @CrohnsColitisFn 2 posters of distinction in understanding perianal #crohnsdisease @Siyan_Cao & preventing perianal CD collab @JeffMcCurdy4, work in SPARC-IBD @AnkitaTirath & 2022 Best Research article award @IBDJournals @WUGastro @IbdWustl
10
12
84
@charlie_lees
Charlie Lees
3 years
Tofacitinib failed in clinical trials for Crohn's disease This may be partly due to the trial design and partly limited by the dose We have used it off-label with some success in a handful of patients The TROPIC consortium reported effectiveness in a cohort with n=79
1
1
8
@john_damianosMD
John Damianos, M.D.
3 years
Excited to present our work on idiopathic myointimal hyperplasia of the mesenteric veins! 💩rare cause of colonic ischemia ✂️surgery = curative 🩸compared with ischemic colitis, patients are more likely to be male, younger, have rectal involvement, & less likely to bleed ACG2022
1
6
46
@Marcfenster1
Marc Fenster
3 years
Our paper in @AGA_CGH looking at Rare, Overlooked, or Underappreciated Causes of Recurrent Abdominal Pain: A Primer for Gastroenterologists Thanks to @umfoodoc @dbrennerGIMD and my mentor #DrBrandt @MonteGastro for including me in this important work https://t.co/91MKLqvgLy
3
33
113
@john_damianosMD
John Damianos, M.D.
3 years
Rare, overlooked, or underappreciated causes of recurrent abdominal pain #MedTwitter #GITwitter https://t.co/RZEIiMypeJ
2
19
72
@NCostable
Nicholas Costable, MD
3 years
Exciting things happening here at the #BronxLiveEndoscopyCourse! A Zenker’s diverticulotomy using a SB Knife with Sammy Ho, featuring our fantastic panelists @JonathanBuscag1, @dagreenwald, Meera Bhardwaj and Dr Brandt @MonteGastro @MonteNYCliver @josephwrinaldi
0
2
10
@P_DeepakIBDMD
Parakkal Deepak MD, MS, FACG
4 years
👇🏼Will need real world studies for understanding positioning, predictors #TROPIC consortium @AndresYarur @ryanungaro @IBDBen @amjohnsonMD @GauravsyalMD @Marcfenster1 @jpekowmd @IBDMD @tinahamd @JeanFredericCo1
@fgomollon
Fernando Gomollón
4 years
Exciting news from #ECCO2022: upadacitinib, guselkumab, mirikizumab, risankizumab, filgotinib, ozanimod, etrasimod: all working in #IBD. Very good prospects, problems will be mainly three: predicting, choosing, and, particularly, access. @geteccu #somosGETECCU
0
2
7
@Marcfenster1
Marc Fenster
4 years
Great working with @JeanFredericCo1 @P_DeepakIBDMD @QuazimAlayo on this important study- see thread with key points highlighted
@P_DeepakIBDMD
Parakkal Deepak MD, MS, FACG
4 years
TY @EdwardLoftus2 👉13 studies (1 clinical trial, 12 observational studies) 👉266 patients 👉7 combinations 👉 Median duration follow-up 16-68 weeks 👉 Pooled rates SAE 9.6% (95% CI, 1.5–21.4) VDZ-aTNF & 1.0% (95% CI, 0.0–7.6) for Tofa-VDZ. Link:
1
1
12